Phage-Based Pesticide for Varroa Mite Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Varroa destructor infestation in honey bee colonies are ineffective due to harsh chemicals that persist in the hive and lead to bee harm, and the development of chemical pesticide resistance in mites, necessitating a biorational option that targets the mite's specific microbiome without harming the bees.
Innovation Solution
A phage-based therapy using bacteriophages with specificity for Bacillus sp., Hafnia sp., and Escherichia sp. bacteria within Varroa destructor, which disrupts the mite's microbiome, causing sickness or death without affecting the honey bee microbiota, thereby controlling and eliminating the mite population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If harsh chemical pesticides are used to treat Varroa destructor infestation, then the mite population is reduced, but the chemicals persist in the hive and harm honey bees
Solution Approach 1:
The patent uses bacteriophages as an intermediary agent to treat Varroa destructor mites. Instead of applying chemicals directly to bees (which causes harm), the phages are administered to the hive environment where they selectively infect and kill mites through their bacterial hosts, eliminating the need for harmful chemical intermediaries that persist in the hive
Solution Approach 2:
The patent replaces the mechanical/chemical pesticide system with a biological system based on bacteriophages. The chemical mechanism of toxic killing is substituted with a biological mechanism of selective viral infection, which naturally degrades without persistence and targets only the intended pest population
2Reliability
If chemical pesticides are used repeatedly to control Varroa destructor, then initial mite populations are reduced, but mites develop resistance over time
Solution Approach 1:
The patent changes the fundamental parameter of the treatment mechanism from chemical toxicity to biological specificity. By using bacteriophages with narrow host ranges that target specific bacteria within Varroa destructor, the treatment mechanism operates through a different parameter (viral infectivity) that does not induce resistance in the same way chemicals do
Solution Approach 2:
The patent introduces bacteriophages as a new intermediary that acts through a different biological pathway. Rather than chemicals directly killing mites, the phages infect mite-associated bacteria, creating a multi-step biological control mechanism that bypasses the resistance development pathway of direct chemical exposure
3Reliability
If broad-spectrum treatments are used to eliminate Varroa destructor, then mite populations are reduced, but beneficial bee microbiota are also affected
Solution Approach 1:
The patent applies the principle of local quality by using bacteriophages with highly specific host ranges that target only particular bacteria species associated with Varroa destructor. This localized specificity ensures that only the intended mite-associated bacteria are affected, while beneficial bee microbiota with different bacterial compositions remain untouched
Solution Approach 2:
The treatment creates a localized effect within the mite population rather than affecting the entire hive ecosystem uniformly. The phages concentrate their action on mite-associated bacteria through the mites themselves as delivery vehicles, leaving bee microbiota in different locations and environments unaffected
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The phage-based therapy effectively reduces Varroa destructor populations, supporting bee health and hive longevity by specifically targeting beneficial bacteria in the mites, thereby preserving the bees and hive from infestation-induced collapse.
Implementation Method 1
compositions and methods for use in preserving a beehive or bees associated with the beehive against Varroa destructor infestation-induced collapse or death, or supporting the health, vitality, and longevity of a beehive or bees associated with the beehive by controlling, reducing, or eliminating a population of Varroa destructor associated with the beehive or bees associated with the beehive through targeted, phage-based, bactericidal or bacteriostatic activity
Data Source
AI summary
Compositions and methods for use in preserving a beehive or bees associated with the beehive against Varroa destructor infestation-induced collapse or death, or supporting the health, vitality, and longevity of a beehive or bees associated with the beehive by controlling, reducing, or eliminating a population of Varroa destructor associated with the beehive or bees associated with the beehive through targeted, phage-based, bactericidal or bacteriostatic activity against Bacillus sp., Hafnia sp., and/or Escherichia sp. present in Varroa destructor associated with the beehive or bees associated with the beehive, and specifically by applying or administering to the beehive, or to bees associated with the beehive, a composition comprising one or more bacteriophage having cellular tropism for, or infectivity specific for, Bacillus sp., Hafnia sp., and/or Escherichia sp. in Varroa destructor associated with the beehive or bees associated with the beehive.